Paclitaxel-Coated Balloon Effective for Coronary In-Stent Restenosis
By Elana Gotkine HealthDay Reporter
MONDAY, March 11, 2024 -- A paclitaxel-coated balloon is superior to an uncoated balloon for the composite end point of target lesion failure among patients undergoing coronary angioplasty for in-stent restenosis, according to a study published online March 9 in the Journal of the American Medical Association to coincide with Cardiovascular Research Technologies 2024, held from March 9 to 12 in Washington, D.C.
Robert W. Yeh, M.D., from the Beth Israel Deaconess Medical Center in Boston, and colleagues examined whether a paclitaxel-coated balloon is superior to an uncoated balloon in 600 patients with in-stent restenosis undergoing percutaneous coronary intervention at 40 centers. Participants were randomly assigned to undergo treatment with a paclitaxel-coated or uncoated balloon (406 and 194 patients, respectively).
The researchers found that the primary end point of one-year target lesion failure occurred in 17.9 and 28.6 percent of patients in the paclitaxel-coated and uncoated balloon groups, respectively, meeting the criteria for superiority (hazard ratio, 0.59). Patients treated with paclitaxel-coated balloon less often had target lesion revascularization and target vessel-related myocardial infarction (hazard ratios, 0.50 and 0.51, respectively). In the coated versus uncoated balloon groups, the rate of cardiac death was not significantly different (2.9 versus 1.6 percent).
"Paclitaxel-coated balloons are an effective treatment option for patients with coronary in-stent restenosis," the authors write.
Several authors disclosed ties to pharmaceutical and biotechnology companies, including Boston Scientific, which funded the study.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted March 2024
Read this next
In-Hospital Mortality Rare After Percutaneous Coronary Intervention
MONDAY, April 15, 2024 -- In-hospital mortality is rare after percutaneous coronary intervention (PCI) and is most commonly related to prior cardiovascular condition, according to...
CAC Score Predicts MACE in Patients With Stable Chest Pain
THURSDAY, March 14, 2024 -- For people with stable chest pain referred for invasive coronary angiography (ICA), the risk for major adverse cardiovascular events (MACE) is low...
Long-Term Outcomes Similar for Bioresorbable Vascular Scaffolds Versus Metal Stents
WEDNESDAY, May 24, 2023 -- For patients undergoing percutaneous coronary intervention, first-generation bioresorbable vascular scaffolds (BVS) seem to be as safe as cobalt...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.